TR200100575T2 - Taksoid türevlerinin yeni kullanım alanları - Google Patents

Taksoid türevlerinin yeni kullanım alanları

Info

Publication number
TR200100575T2
TR200100575T2 TR2001/00575T TR200100575T TR200100575T2 TR 200100575 T2 TR200100575 T2 TR 200100575T2 TR 2001/00575 T TR2001/00575 T TR 2001/00575T TR 200100575 T TR200100575 T TR 200100575T TR 200100575 T2 TR200100575 T2 TR 200100575T2
Authority
TR
Turkey
Prior art keywords
taxoid derivatives
new uses
relates
taxoid
derivatives
Prior art date
Application number
TR2001/00575T
Other languages
English (en)
Turkish (tr)
Inventor
Bissery Marie-Christine
Vrignaud Patricia
Roberts Simon
Brealey Clive
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98115650A external-priority patent/EP0982028A1/en
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of TR200100575T2 publication Critical patent/TR200100575T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TR2001/00575T 1998-08-20 1999-08-18 Taksoid türevlerinin yeni kullanım alanları TR200100575T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98115650A EP0982028A1 (en) 1998-08-20 1998-08-20 New use of taxoid derivatives
US12384399P 1999-03-11 1999-03-11

Publications (1)

Publication Number Publication Date
TR200100575T2 true TR200100575T2 (tr) 2001-07-23

Family

ID=26149552

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00575T TR200100575T2 (tr) 1998-08-20 1999-08-18 Taksoid türevlerinin yeni kullanım alanları

Country Status (15)

Country Link
EP (1) EP1105119A2 (et)
JP (1) JP2002523364A (et)
KR (1) KR20010079665A (et)
CN (1) CN1313764A (et)
AU (1) AU5742099A (et)
BG (1) BG105273A (et)
CA (1) CA2341191A1 (et)
EE (1) EE200100082A (et)
HU (1) HUP0104000A3 (et)
IL (1) IL141231A0 (et)
MX (1) MXPA01001721A (et)
NO (1) NO20010655L (et)
SK (1) SK2352001A3 (et)
TR (1) TR200100575T2 (et)
WO (1) WO2000010547A2 (et)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922107B1 (fr) * 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
EP2493466B1 (en) 2009-10-29 2021-03-10 Sanofi Mature IP Novel antitumoral use of cabazitaxel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2732968B1 (fr) * 1995-04-14 1997-05-16 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
WO2000010547A2 (en) 2000-03-02
EE200100082A (et) 2002-06-17
NO20010655D0 (no) 2001-02-07
WO2000010547A3 (en) 2000-06-29
EP1105119A2 (en) 2001-06-13
KR20010079665A (ko) 2001-08-22
HUP0104000A2 (hu) 2002-04-29
HUP0104000A3 (en) 2003-01-28
CN1313764A (zh) 2001-09-19
NO20010655L (no) 2001-02-07
CA2341191A1 (en) 2000-03-02
SK2352001A3 (en) 2001-07-10
MXPA01001721A (es) 2005-06-03
JP2002523364A (ja) 2002-07-30
AU5742099A (en) 2000-03-14
BG105273A (en) 2001-11-30
IL141231A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
NZ308789A (en) Tetralin derivatives and medicaments
TR200401264T4 (tr) CB1-reseptör-antagonistiyle-sibütramin birleşimi, bunları içeren farmasötik-bileşimler ve obezite tedavisinde kullanımları.
TR199800644T2 (xx) Bir apoptoz inhibit�r� olarak y-RAR antagonist ligand� ya da alfa-RAR antagonist ligand�.
Marques et al. Micronuclei and sister chromatid exchanges induced by capsaicin in human lymphocytes
Cherek et al. Laboratory measures: point subtraction aggression paradigm
Jones A long look at the adrenogenital syndrome
De et al. Tacrolimus‐induced hyperpigmentation in a patch of vitiligo
Stamler Who will be effective as a clinical trials investigator and what are adequate incentives? Appendix 1: A proposed mechanism and set of criteria for the evaluation of the scientific contribution of individual investigators in collaborative studies, including large clinical trials
NO20010655L (no) Ny anvendelse av taxoidderivater
BR9913071A (pt) Uso de um composto derivado de taxóide
Lincoln Proclamation of a National Fast Day; Meditation on the Divine Will
Min et al. Chuvash Polycythemia Patients from Afghanistan and Southern India share a common VHL gene haplotype. Support for its origin before Asians and Europeans diverged
Sundar Caffeic Acid Phenethyl Ester and Withaferin-A Combination Selectively Inhibits Ternary Complex Formed by p53, Mortalin and PARP1
Reed et al. The African Church
Raychaudhuri DP Sidhu, A new relation among neutrino neutral current couplings and a constraint on the electron weak neutral current couplings, Phys. Lett. 87B (1979) 67.
Su et al. Natural Lignan Justicidin A‐Enhanced Mitophagy and Mitogenesis in Cytotoxicity of Grade III Human Bladder Cancer Cells
Saeki et al. Inhibitory effect of tyrosine phosphatase inhibitor on peroxynitrite-induced cell death
Rice et al. Northern Europe: Scandinavia, Finland, and the Baltic States
RIALS et al. I MPLANTABLE CARDIOVERTER-DTP SCD
Murden et al. The Effect of Phytochemicals on a Chemoresistant, Epithelial‐Mesenchymal Transitioned, Colorectal Cancer Cell Line
Storey Some late nineteenth-century views of Clare: 1887, 1893, 1897
Bassett Eclampsia in three generations of the same family
Chan et al. Suppression of valid inferences: syntactic views, mental models, and relative salience (Cognition, vol. 53, no. 3 (1994), pp. 217-238)~
Yadegarynia et al. Evaluation of flavonoids as agents to inhibit breast cancer
Schuman Generational Effects: Past, Present, and Future